Table 2 LOT transition among patients with > 1 LOT
LOT1 | LOT2 (N = 229) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pazopanib | Docetaxel, gemcitabine | Doxorubicin | Gemcitabine | Temozolomide | Others | |||||||
(N = 43, 18.8%) | (N = 38, 16.6%) | (N = 24, 10.5%) | (N = 9, 3.9%) | (N = 8, 3.5%) | (N = 107, 46.7%) | |||||||
n | % | n | % | n | % | n | % | n | % | n | % | |
Docetaxel, gemcitabine | 20 | 46.5 | 5 | 13.2 | 14 | 58.3 | 0 | 0.0 | 0 | 0.0 | 19 | 17.8 |
Doxorubicin | 4 | 9.3 | 12 | 31.6 | 1 | 4.2 | 1 | 11.1 | 2 | 25.0 | 13 | 12.2 |
Pazopanib | 3 | 7.0 | 4 | 10.5 | 1 | 4.2 | 3 | 33.3 | 2 | 25.0 | 4 | 3.7 |
Doxorubicin, ifosfamide | 3 | 7.0 | 5 | 13.2 | 0 | 0.0 | 1 | 11.1 | 0 | 0.0 | 2 | 1.9 |
Gemcitabine | 2 | 4.7 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 6 | 5.6 |
Others | 11 | 25.6 | 12 | 31.6 | 8 | 33.3 | 4 | 44.4 | 4 | 50.0 | 63 | 58.9 |
LOT2 | LOT3 (N = 88) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pazopanib | Doxorubicin | Eribulin mesylate | Docetaxel, gemcitabine | Temozolomide | Others | |||||||
(N = 27, 30.7%) | (N = 12, 13.6%) | (N = 6, 6.8%) | (N = 5, 5.7%) | (N = 4, 4.5%) | (N = 34, 38.6%) | |||||||
n | % | n | % | n | % | n | % | n | % | n | % | |
Pazopanib | 4 | 14.8 | 5 | 41.7 | 0 | 0.0 | 0 | 0.0 | 2 | 50.0 | 5 | 14.7 |
Docetaxel, gemcitabine | 8 | 29.6 | 2 | 16.7 | 0 | 0.0 | 1 | 20.0 | 0 | 0.0 | 2 | 5.9 |
Doxorubicin | 4 | 14.8 | 1 | 8.3 | 1 | 16.7 | 1 | 20.0 | 0 | 0.0 | 4 | 11.8 |
Gemcitabine | 1 | 3.7 | 2 | 16.7 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 5.9 |
Temozolomide | 2 | 7.4 | 0 | 0.0 | 0 | 0.0 | 1 | 20.0 | 0 | 0.0 | 3 | 8.8 |
Others | 8 | 29.6 | 2 | 16.7 | 5 | 83.3 | 2 | 40.0 | 2 | 50.0 | 18 | 52.9 |